New drug combo tested to control advanced ovarian cancer before surgery
NCT ID NCT07322094
Summary
This study is testing whether adding an experimental drug called TORL-1-23 to standard chemotherapy helps control advanced ovarian cancer before surgery. It will involve 60 women with newly diagnosed, advanced-stage ovarian, fallopian tube, or primary peritoneal cancer whose tumors test positive for a marker called CLDN6. The main goals are to see if the combination is safe and if it helps shrink tumors effectively before surgical removal.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.